One molecule, three price tags: NMN, NR, and the $1,000 NAD+ drip, compared

Editorial evidence review — September 22, 2026

Walk into a longevity clinic, scroll a supplement storefront, or sit through a wellness podcast’s ad read, and you will meet the same molecule three times at three price points. Nicotinamide adenine dinucleotide — NAD+ — can be pursued with a bottle of NMN capsules for roughly a dollar a day, with nicotinamide riboside (NR) for about the same, or with an intravenous NAD+ infusion that clinics price anywhere from $250 to $1,000 a session. None of the three is a peptide — NAD+ is a coenzyme and its precursors are nucleotide chemistry — but the NAD+ menu is sold from the same clinic pages, stacked in the same protocols, and pitched with the same vocabulary as the peptide economy we cover, which is why this site tracks it.

The market’s implied logic is that more money buys a more direct route: pills are the entry level, the drip is the premium product. Over the past twelve months, that logic has become testable. A head-to-head randomized trial published in Nature Metabolism in January 2026 directly compared the oral precursors for the first time. An October 2025 review in the same journal assessed what all of this NAD+ raising has actually done for human health. And the FDA classified its first Class I recall — the category reserved for products that can kill — in the injectable-NAD+ supply chain. Line the three routes up against the evidence, and they rank in exactly the opposite order of the price list.

The first question: does the NAD+ number go up?

The entire category rests on one biochemical premise: NAD+ is a central redox cofactor and enzyme substrate, its measured levels decline with age in at least some tissues, and restoring it should restore function. The premise’s last clause is the contested one — but start with the measurable part, because 2026 finally produced the comparison shoppers had been asking for.

In January 2026, Nature Metabolism published the first randomized head-to-head human trial of the three major oral NAD+ boosters (Christen et al.) — NMN, NR, and plain nicotinamide — against placebo in 65 healthy adults over 14 days. The result: NR and NMN raised whole-blood NAD+ substantially and statistically indistinguishably from each other — increases of roughly 49 and 43 µM over placebo, respectively — while plain nicotinamide produced only a transient bump that faded within hours. The mechanistic finding was the surprise: much of the oral precursors’ effect appears to route through the gut microbiome, which converts NMN and NR to nicotinic acid before absorption. The elegant marketing narratives about NMN and NR slipping intact into cells to feed the salvage pathway have, at minimum, a large bacterial asterisk.

Two practical conclusions follow. First, on the endpoint everyone in this market agrees on — circulating NAD+ — the two oral precursors are interchangeable commodities, whatever the comparative-superiority marketing on either side claims. Second, the cheapest tier of the market demonstrably does the thing it says on the label. Hold that thought for the IV section.

The second question: does raising the number help the person?

Here the record is far less obliging, and it is not for lack of study. Oral NR alone has been through more than two dozen published human trials; NMN has been through at least a dozen. The pattern across them is remarkably consistent: the biomarker moves, the clinical outcomes mostly don’t.

The most-cited NMN result remains Yoshino et al.’s 2021 trial in Science: 250 mg/day for 10 weeks improved insulin-stimulated glucose disposal in 25 postmenopausal women with prediabetes — a real signal, in a small selected group, that did not extend to weight, fasting glucose, HbA1c, or lipids, and whose randomization was publicly disputed in the journal’s own pages. On the NR side, Martens et al. 2018 found exploratory blood-pressure signals; Dollerup et al. 2018 found no improvement in insulin sensitivity in obese men; the NICE trial (2024) found a modest six-minute-walk improvement in peripheral artery disease that its own authors framed as grounds for a larger trial rather than a result; and a 2025 long-COVID RCT missed its primary endpoint. A 2023 critical review in Science Advances that went through all 25 published human NR studies concluded that supplementation “has displayed few clinically relevant effects” — and noted the field’s tendency to exaggerate the ones it has. A 2025 systematic review and meta-analysis (Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle) concluded the evidence does not support either NMN or NR for preserving muscle mass or function in older adults — the exact population and promise at the center of the longevity pitch.

The field’s own senior reviewers now say this plainly. An October 2025 review in Nature Metabolism on NAD+ precursor supplementation in human ageing put it in one sentence: preclinical data are promising, and “human clinical trials have shown limited efficacy.” Even the age-related NAD+ decline itself, the review notes, has been consistently observed in humans only in a limited number of studies. This is not a fringe skeptic’s position; it is the field’s flagship journal describing its own clinical record.

To be fair to the pills: that record comes with a genuinely reassuring safety file. NR was tolerated at 3,000 mg per day for four weeks in the NR-SAFE Parkinson’s trial without a safety signal; Conze et al. followed 140 adults for eight weeks without concerning findings; NMN trials up to 1,250 mg/day report the same. The honest summary of oral NAD+ precursors in 2026 is: cheap, benign, reliably move a biomarker, and so far clinically underwhelming everywhere it counts.

The third question: what does the $1,000 version add?

If the market’s pricing tracked evidence, the IV route would carry the strongest file. It carries the weakest one in the entire NAD+ economy.

The published human literature on intravenous NAD+ is, essentially, two studies. Grant et al. 2019 infused NAD+ into eight healthy men over six hours and measured what happened: plasma NAD+ did not rise at all for the first two hours, and the metabolite pattern suggested the infused molecule was being rapidly degraded and excreted — including a surge of NAD+ and its breakdown products in urine. The one clinical-outcome trial is Yu et al. 2026: a single-center randomized trial in 180 hospitalized Chinese patients with heart failure from ischemic cardiomyopathy, in which seven days of IV NAD+ produced a three-point ejection-fraction advantage at one month with non-significant secondaries. That is an interesting cardiology lead in a narrow inpatient population. It is not evidence for energy, focus, hangover recovery, addiction treatment, or longevity in a wellness-clinic chair — the indications the drip is actually sold for, none of which has a single published randomized trial behind it.

The scientists closest to NAD+ biology have said the quiet part on the record. Eric Verdin — CEO of the Buck Institute for Research on Aging, whose lab works on NAD+ — has said flatly that IV NAD+ “is not something that should be done”, because extracellular NAD+ is largely broken down before it can reach the intracellular compartments where it matters. Andrew Huberman, describing his own infusions, acknowledged that “there is no clinical trial exploring NAD+ infusion for the sake of vigor.” The mechanistic irony is sharp: the oral routes work partly because gut bacteria and the liver convert them into usable currency — the “direct” IV route bypasses the conversion machinery and hands the raw coenzyme to plasma enzymes that shred it.

Where the actual documented harms are

Safety is where the price-evidence inversion stops being an academic point. The oral precursors’ documented risk profile, across dozens of trials, amounts to mild GI complaints. The injectable route now has a genuinely dark 12 months on the federal record — all of it, notably, about the products rather than the molecule.

The sequence, laid out in FDA documents: in 2024 the agency warned that compounders were making IV NAD+ from food-grade powder unsuited to sterile injection, citing reports of severe chills, shaking, and vomiting after NAD+ injections. In July 2025, Texas outsourcing facility GenoGenix recalled its NAD+ injection after three patients developed hypotension, uncontrollable shaking, and body aches during or shortly after administration; an unopened vial from the same lot contained excessive bacterial endotoxins. In October 2025, FDA classified that recall Class I — its most serious category, reserved for defects that can cause serious harm or death — and in January 2026 it issued the firm a warning letter spelling out that NAD+ is not eligible for 503B compounding at all. A February 2026 warning letter to a Colorado wellness clinic treated its NAD+ 50 mg/mL injections as unapproved new drugs. As we detailed in our compounded-therapy safety review, sterile injectables are the highest-stakes corner of the compounding world — and the NAD+ drip market has now produced the reference case.

The regulatory ledger completes the inversion. NMN spent 2022–2025 in supplement-status limbo before FDA reversed itself on September 29, 2025 and concluded NMN is not excluded from the dietary-supplement definition — it is lawful on shelves again. NR never left them. Injectable NAD+, meanwhile, sits in FDA’s 503A “Category 1, under evaluation” holding pattern — interim enforcement discretion, not approval — with no 503B pathway and a growing enforcement file, as our NAD+ injectable reference page details. Even the market itself has started routing around the problem: since late 2024, ChromaDex has been supplying pharmaceutical-grade NR to clinics as “Niagen Plus” IV and injections through compounding pharmacies — implicit acknowledgment from the industry’s most established player that the existing NAD+ drip supply chain had a quality problem. What injectable NR does not have, any more than injectable NAD+, is a published efficacy trial for the uses being sold.

The bottom line

Ranked by evidence, the NAD+ menu inverts its own price list. The ~$1-a-day oral precursors are the only tier proven to do what they claim at the biochemical level — and the January 2026 head-to-head makes NMN and NR interchangeable on that endpoint, whichever is cheaper on the day. One tier up in price, nothing changes but the branding. And the $250–$1,000 drip at the top is the one route with evidence it may not even deliver the molecule where it needs to go, zero published trials for any indication it is sold for, explicit skepticism from the field’s own senior scientists, and the market’s only Class I recall. What none of the three tiers has, after a decade and hundreds of millions in sales, is a demonstration that raising NAD+ makes a healthy human live longer, think better, or age slower. The pills are a cheap, safe bet on a hypothesis the field itself now describes as clinically unproven. The drip is an expensive bet against the pharmacology, placed in the one corner of this market where the product in the bag has actually hurt people.

This is an editorial evidence review, not medical advice. Decisions about supplements and infusion therapies belong with a licensed clinician who can weigh your individual history — including the difference between a lawful dietary supplement and a compounded injectable with no approved application.